Mohammed Haneefa Nizamudeen/iStock via Getty Images Today, we are circling back on Harmony Biosciences (NASDAQ:HRMY) for the first time since our last article on this small biopharma name in March 2023. The company has received some more favorable analyst firm coverage recently, and also recently garnered an approval for a label extension. Harmony has made several recent acquisitions to expand its pipeline as well. The company just reported second quarter results. Still, a decent amount of the overall float ...